nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—ABCB1—ovarian cancer	0.113	1	CbGaD
Pazopanib—ABCG2—Topotecan—ovarian cancer	0.0566	0.208	CbGbCtD
Pazopanib—ABCG2—Paclitaxel—ovarian cancer	0.028	0.103	CbGbCtD
Pazopanib—ABCG2—Carboplatin—ovarian cancer	0.0264	0.0969	CbGbCtD
Pazopanib—ABCB1—Topotecan—ovarian cancer	0.0204	0.075	CbGbCtD
Pazopanib—ABCG2—Docetaxel—ovarian cancer	0.0203	0.0744	CbGbCtD
Pazopanib—ABCG2—Doxorubicin—ovarian cancer	0.0151	0.0555	CbGbCtD
Pazopanib—CYP2C8—Paclitaxel—ovarian cancer	0.0149	0.0548	CbGbCtD
Pazopanib—ABCB1—Vinorelbine—ovarian cancer	0.0144	0.0528	CbGbCtD
Pazopanib—CYP2D6—Vinorelbine—ovarian cancer	0.0136	0.0498	CbGbCtD
Pazopanib—CYP3A4—Topotecan—ovarian cancer	0.0122	0.0449	CbGbCtD
Pazopanib—ABCB1—Paclitaxel—ovarian cancer	0.0101	0.0371	CbGbCtD
Pazopanib—CYP3A4—Vinorelbine—ovarian cancer	0.00862	0.0317	CbGbCtD
Pazopanib—ABCB1—Docetaxel—ovarian cancer	0.00731	0.0268	CbGbCtD
Pazopanib—CYP3A4—Paclitaxel—ovarian cancer	0.00606	0.0222	CbGbCtD
Pazopanib—ABCB1—Doxorubicin—ovarian cancer	0.00545	0.02	CbGbCtD
Pazopanib—CYP2D6—Doxorubicin—ovarian cancer	0.00513	0.0189	CbGbCtD
Pazopanib—CYP3A4—Docetaxel—ovarian cancer	0.00438	0.0161	CbGbCtD
Pazopanib—CYP3A4—Doxorubicin—ovarian cancer	0.00326	0.012	CbGbCtD
Pazopanib—Rilpivirine—ABCB1—ovarian cancer	0.00106	1	CrCbGaD
Pazopanib—PLK4—Idarubicin—Epirubicin—ovarian cancer	0.000784	0.26	CbGdCrCtD
Pazopanib—PLK4—Doxorubicin—Epirubicin—ovarian cancer	0.000784	0.26	CbGdCrCtD
Pazopanib—LIMK2—endometrium—ovarian cancer	0.000733	0.00428	CbGeAlD
Pazopanib—FLT1—myometrium—ovarian cancer	0.000728	0.00425	CbGeAlD
Pazopanib—PLK4—Epirubicin—Doxorubicin—ovarian cancer	0.000726	0.24	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Doxorubicin—ovarian cancer	0.000726	0.24	CbGdCrCtD
Pazopanib—PIP4K2C—uterine cervix—ovarian cancer	0.000724	0.00423	CbGeAlD
Pazopanib—EPHB6—myometrium—ovarian cancer	0.000719	0.0042	CbGeAlD
Pazopanib—FGFR1—uterine cervix—ovarian cancer	0.000719	0.0042	CbGeAlD
Pazopanib—TAOK1—testis—ovarian cancer	0.000716	0.00418	CbGeAlD
Pazopanib—STK16—female reproductive system—ovarian cancer	0.00071	0.00415	CbGeAlD
Pazopanib—PLK4—bone marrow—ovarian cancer	0.00071	0.00415	CbGeAlD
Pazopanib—STK36—gonad—ovarian cancer	0.000703	0.00411	CbGeAlD
Pazopanib—FLT1—embryo—ovarian cancer	0.0007	0.00409	CbGeAlD
Pazopanib—FGFR3—female reproductive system—ovarian cancer	0.000699	0.00409	CbGeAlD
Pazopanib—RIOK2—female reproductive system—ovarian cancer	0.000699	0.00409	CbGeAlD
Pazopanib—FLT4—decidua—ovarian cancer	0.000694	0.00406	CbGeAlD
Pazopanib—PI4KB—gonad—ovarian cancer	0.000693	0.00405	CbGeAlD
Pazopanib—BMPR1B—female reproductive system—ovarian cancer	0.000692	0.00405	CbGeAlD
Pazopanib—MAP3K19—female reproductive system—ovarian cancer	0.000692	0.00405	CbGeAlD
Pazopanib—MAP3K9—lymph node—ovarian cancer	0.000691	0.00404	CbGeAlD
Pazopanib—PIP4K2C—decidua—ovarian cancer	0.00069	0.00403	CbGeAlD
Pazopanib—STK10—myometrium—ovarian cancer	0.000689	0.00403	CbGeAlD
Pazopanib—PI4KB—uterus—ovarian cancer	0.000688	0.00402	CbGeAlD
Pazopanib—MAP3K2—uterine cervix—ovarian cancer	0.000687	0.00401	CbGeAlD
Pazopanib—TAOK3—myometrium—ovarian cancer	0.000686	0.00401	CbGeAlD
Pazopanib—FGFR1—decidua—ovarian cancer	0.000685	0.004	CbGeAlD
Pazopanib—LIMK2—gonad—ovarian cancer	0.00068	0.00397	CbGeAlD
Pazopanib—LIMK2—uterus—ovarian cancer	0.000675	0.00395	CbGeAlD
Pazopanib—SH2B3—testis—ovarian cancer	0.000674	0.00394	CbGeAlD
Pazopanib—AURKC—testis—ovarian cancer	0.000664	0.00388	CbGeAlD
Pazopanib—RIOK2—bone marrow—ovarian cancer	0.00066	0.00386	CbGeAlD
Pazopanib—PDGFRA—embryo—ovarian cancer	0.000656	0.00383	CbGeAlD
Pazopanib—PIP4K2C—endometrium—ovarian cancer	0.000655	0.00383	CbGeAlD
Pazopanib—FGF1—epithelium—ovarian cancer	0.000652	0.00381	CbGeAlD
Pazopanib—STK16—female gonad—ovarian cancer	0.000646	0.00378	CbGeAlD
Pazopanib—LCK—uterine cervix—ovarian cancer	0.000643	0.00376	CbGeAlD
Pazopanib—STK16—vagina—ovarian cancer	0.000642	0.00375	CbGeAlD
Pazopanib—RIOK2—female gonad—ovarian cancer	0.000636	0.00372	CbGeAlD
Pazopanib—RIOK2—vagina—ovarian cancer	0.000632	0.0037	CbGeAlD
Pazopanib—BMPR1B—female gonad—ovarian cancer	0.00063	0.00368	CbGeAlD
Pazopanib—STK36—female reproductive system—ovarian cancer	0.000628	0.00367	CbGeAlD
Pazopanib—PI4KB—female reproductive system—ovarian cancer	0.000619	0.00361	CbGeAlD
Pazopanib—FGFR2—epithelium—ovarian cancer	0.000616	0.0036	CbGeAlD
Pazopanib—KDR—myometrium—ovarian cancer	0.000615	0.00359	CbGeAlD
Pazopanib—MAP2K5—myometrium—ovarian cancer	0.000615	0.00359	CbGeAlD
Pazopanib—LCK—decidua—ovarian cancer	0.000613	0.00358	CbGeAlD
Pazopanib—FGFR2—uterine cervix—ovarian cancer	0.000611	0.00357	CbGeAlD
Pazopanib—PIP4K2C—gonad—ovarian cancer	0.000608	0.00355	CbGeAlD
Pazopanib—LIMK2—female reproductive system—ovarian cancer	0.000607	0.00355	CbGeAlD
Pazopanib—PLK4—testis—ovarian cancer	0.000607	0.00355	CbGeAlD
Pazopanib—CSF1R—myometrium—ovarian cancer	0.0006	0.00351	CbGeAlD
Pazopanib—FGFR1—uterus—ovarian cancer	0.000599	0.0035	CbGeAlD
Pazopanib—KDR—embryo—ovarian cancer	0.000592	0.00346	CbGeAlD
Pazopanib—PI4KB—bone marrow—ovarian cancer	0.000584	0.00341	CbGeAlD
Pazopanib—CSF1R—embryo—ovarian cancer	0.000577	0.00337	CbGeAlD
Pazopanib—MAP3K2—gonad—ovarian cancer	0.000576	0.00337	CbGeAlD
Pazopanib—STK16—testis—ovarian cancer	0.000573	0.00335	CbGeAlD
Pazopanib—MAP3K2—uterus—ovarian cancer	0.000572	0.00334	CbGeAlD
Pazopanib—STK36—female gonad—ovarian cancer	0.000572	0.00334	CbGeAlD
Pazopanib—FLT1—epithelium—ovarian cancer	0.000571	0.00334	CbGeAlD
Pazopanib—ITK—lymph node—ovarian cancer	0.00057	0.00333	CbGeAlD
Pazopanib—STK36—vagina—ovarian cancer	0.000568	0.00332	CbGeAlD
Pazopanib—FLT1—uterine cervix—ovarian cancer	0.000566	0.00331	CbGeAlD
Pazopanib—FGFR3—testis—ovarian cancer	0.000564	0.0033	CbGeAlD
Pazopanib—RIOK2—testis—ovarian cancer	0.000564	0.0033	CbGeAlD
Pazopanib—PI4KB—female gonad—ovarian cancer	0.000563	0.00329	CbGeAlD
Pazopanib—EPHB6—uterine cervix—ovarian cancer	0.00056	0.00327	CbGeAlD
Pazopanib—PI4KB—vagina—ovarian cancer	0.000559	0.00327	CbGeAlD
Pazopanib—BMPR1B—testis—ovarian cancer	0.000559	0.00326	CbGeAlD
Pazopanib—MAP3K19—testis—ovarian cancer	0.000559	0.00326	CbGeAlD
Pazopanib—LIMK2—female gonad—ovarian cancer	0.000553	0.00323	CbGeAlD
Pazopanib—LIMK2—vagina—ovarian cancer	0.000549	0.00321	CbGeAlD
Pazopanib—FLT4—female reproductive system—ovarian cancer	0.000546	0.00319	CbGeAlD
Pazopanib—KIT—myometrium—ovarian cancer	0.000545	0.00319	CbGeAlD
Pazopanib—PIP4K2C—female reproductive system—ovarian cancer	0.000543	0.00317	CbGeAlD
Pazopanib—FLT1—decidua—ovarian cancer	0.00054	0.00315	CbGeAlD
Pazopanib—STK10—uterine cervix—ovarian cancer	0.000536	0.00313	CbGeAlD
Pazopanib—LCK—uterus—ovarian cancer	0.000536	0.00313	CbGeAlD
Pazopanib—TAOK3—uterine cervix—ovarian cancer	0.000534	0.00312	CbGeAlD
Pazopanib—EPHB6—decidua—ovarian cancer	0.000533	0.00312	CbGeAlD
Pazopanib—PDGFRB—myometrium—ovarian cancer	0.000532	0.00311	CbGeAlD
Pazopanib—KIT—embryo—ovarian cancer	0.000524	0.00306	CbGeAlD
Pazopanib—TAOK1—lymph node—ovarian cancer	0.000519	0.00303	CbGeAlD
Pazopanib—FLT4—bone marrow—ovarian cancer	0.000515	0.00301	CbGeAlD
Pazopanib—MAP3K2—female reproductive system—ovarian cancer	0.000514	0.00301	CbGeAlD
Pazopanib—PIP4K2C—bone marrow—ovarian cancer	0.000512	0.00299	CbGeAlD
Pazopanib—FLT1—endometrium—ovarian cancer	0.000512	0.00299	CbGeAlD
Pazopanib—PDGFRB—embryo—ovarian cancer	0.000512	0.00299	CbGeAlD
Pazopanib—STK10—decidua—ovarian cancer	0.000511	0.00298	CbGeAlD
Pazopanib—FGFR2—uterus—ovarian cancer	0.000509	0.00298	CbGeAlD
Pazopanib—TAOK3—decidua—ovarian cancer	0.000509	0.00297	CbGeAlD
Pazopanib—STK36—testis—ovarian cancer	0.000507	0.00296	CbGeAlD
Pazopanib—EPHB6—endometrium—ovarian cancer	0.000506	0.00296	CbGeAlD
Pazopanib—PDGFRA—decidua—ovarian cancer	0.000506	0.00295	CbGeAlD
Pazopanib—PI4KB—testis—ovarian cancer	0.000499	0.00292	CbGeAlD
Pazopanib—FLT4—female gonad—ovarian cancer	0.000497	0.0029	CbGeAlD
Pazopanib—PIP4K2C—female gonad—ovarian cancer	0.000494	0.00289	CbGeAlD
Pazopanib—PIP4K2C—vagina—ovarian cancer	0.000491	0.00287	CbGeAlD
Pazopanib—LIMK2—testis—ovarian cancer	0.00049	0.00286	CbGeAlD
Pazopanib—FGFR1—female gonad—ovarian cancer	0.00049	0.00286	CbGeAlD
Pazopanib—SH2B3—lymph node—ovarian cancer	0.000489	0.00286	CbGeAlD
Pazopanib—FGFR1—vagina—ovarian cancer	0.000487	0.00285	CbGeAlD
Pazopanib—MAP3K2—bone marrow—ovarian cancer	0.000486	0.00284	CbGeAlD
Pazopanib—FGF1—female reproductive system—ovarian cancer	0.000485	0.00283	CbGeAlD
Pazopanib—TAOK3—endometrium—ovarian cancer	0.000483	0.00282	CbGeAlD
Pazopanib—KDR—epithelium—ovarian cancer	0.000483	0.00282	CbGeAlD
Pazopanib—AURKC—lymph node—ovarian cancer	0.000481	0.00281	CbGeAlD
Pazopanib—KDR—uterine cervix—ovarian cancer	0.000479	0.0028	CbGeAlD
Pazopanib—MAP2K5—uterine cervix—ovarian cancer	0.000479	0.0028	CbGeAlD
Pazopanib—FLT1—gonad—ovarian cancer	0.000475	0.00278	CbGeAlD
Pazopanib—FLT1—uterus—ovarian cancer	0.000472	0.00276	CbGeAlD
Pazopanib—MAP3K2—female gonad—ovarian cancer	0.000468	0.00274	CbGeAlD
Pazopanib—CSF1R—uterine cervix—ovarian cancer	0.000467	0.00273	CbGeAlD
Pazopanib—FGFR2—female reproductive system—ovarian cancer	0.000458	0.00267	CbGeAlD
Pazopanib—KDR—decidua—ovarian cancer	0.000456	0.00267	CbGeAlD
Pazopanib—MAP2K5—decidua—ovarian cancer	0.000456	0.00267	CbGeAlD
Pazopanib—LCK—bone marrow—ovarian cancer	0.000455	0.00266	CbGeAlD
Pazopanib—STK10—gonad—ovarian cancer	0.00045	0.00263	CbGeAlD
Pazopanib—STK10—uterus—ovarian cancer	0.000447	0.00261	CbGeAlD
Pazopanib—PDGFRA—gonad—ovarian cancer	0.000445	0.0026	CbGeAlD
Pazopanib—CSF1R—decidua—ovarian cancer	0.000445	0.0026	CbGeAlD
Pazopanib—TAOK3—uterus—ovarian cancer	0.000445	0.0026	CbGeAlD
Pazopanib—PDGFRA—uterus—ovarian cancer	0.000442	0.00258	CbGeAlD
Pazopanib—FGF1—female gonad—ovarian cancer	0.000441	0.00258	CbGeAlD
Pazopanib—FLT4—testis—ovarian cancer	0.00044	0.00257	CbGeAlD
Pazopanib—PLK4—lymph node—ovarian cancer	0.00044	0.00257	CbGeAlD
Pazopanib—LCK—female gonad—ovarian cancer	0.000438	0.00256	CbGeAlD
Pazopanib—PIP4K2C—testis—ovarian cancer	0.000438	0.00256	CbGeAlD
Pazopanib—LCK—vagina—ovarian cancer	0.000436	0.00255	CbGeAlD
Pazopanib—FGFR1—testis—ovarian cancer	0.000434	0.00254	CbGeAlD
Pazopanib—KDR—endometrium—ovarian cancer	0.000433	0.00253	CbGeAlD
Pazopanib—MAP2K5—endometrium—ovarian cancer	0.000433	0.00253	CbGeAlD
Pazopanib—KIT—epithelium—ovarian cancer	0.000428	0.0025	CbGeAlD
Pazopanib—FLT1—female reproductive system—ovarian cancer	0.000424	0.00248	CbGeAlD
Pazopanib—KIT—uterine cervix—ovarian cancer	0.000424	0.00248	CbGeAlD
Pazopanib—CSF1R—endometrium—ovarian cancer	0.000423	0.00247	CbGeAlD
Pazopanib—PDGFRB—epithelium—ovarian cancer	0.000418	0.00244	CbGeAlD
Pazopanib—FGFR2—female gonad—ovarian cancer	0.000417	0.00243	CbGeAlD
Pazopanib—STK16—lymph node—ovarian cancer	0.000416	0.00243	CbGeAlD
Pazopanib—MAP3K2—testis—ovarian cancer	0.000415	0.00243	CbGeAlD
Pazopanib—PDGFRB—uterine cervix—ovarian cancer	0.000414	0.00242	CbGeAlD
Pazopanib—RIOK2—lymph node—ovarian cancer	0.000409	0.00239	CbGeAlD
Pazopanib—BMPR1B—lymph node—ovarian cancer	0.000405	0.00237	CbGeAlD
Pazopanib—KIT—decidua—ovarian cancer	0.000404	0.00236	CbGeAlD
Pazopanib—STK10—female reproductive system—ovarian cancer	0.000402	0.00235	CbGeAlD
Pazopanib—TAOK3—female reproductive system—ovarian cancer	0.0004	0.00234	CbGeAlD
Pazopanib—KDR—uterus—ovarian cancer	0.000399	0.00233	CbGeAlD
Pazopanib—PDGFRA—female reproductive system—ovarian cancer	0.000398	0.00232	CbGeAlD
Pazopanib—PDGFRB—decidua—ovarian cancer	0.000395	0.00231	CbGeAlD
Pazopanib—CSF1R—gonad—ovarian cancer	0.000392	0.00229	CbGeAlD
Pazopanib—FGF1—testis—ovarian cancer	0.000391	0.00229	CbGeAlD
Pazopanib—CSF1R—uterus—ovarian cancer	0.000389	0.00228	CbGeAlD
Pazopanib—LCK—testis—ovarian cancer	0.000389	0.00227	CbGeAlD
Pazopanib—FLT1—female gonad—ovarian cancer	0.000386	0.00226	CbGeAlD
Pazopanib—FLT1—vagina—ovarian cancer	0.000384	0.00224	CbGeAlD
Pazopanib—KIT—endometrium—ovarian cancer	0.000384	0.00224	CbGeAlD
Pazopanib—EPHB6—female gonad—ovarian cancer	0.000382	0.00223	CbGeAlD
Pazopanib—EPHB6—vagina—ovarian cancer	0.000379	0.00222	CbGeAlD
Pazopanib—STK10—bone marrow—ovarian cancer	0.000379	0.00222	CbGeAlD
Pazopanib—TAOK3—bone marrow—ovarian cancer	0.000378	0.00221	CbGeAlD
Pazopanib—PDGFRB—endometrium—ovarian cancer	0.000375	0.00219	CbGeAlD
Pazopanib—FGFR2—testis—ovarian cancer	0.000369	0.00216	CbGeAlD
Pazopanib—STK36—lymph node—ovarian cancer	0.000367	0.00215	CbGeAlD
Pazopanib—STK10—female gonad—ovarian cancer	0.000365	0.00214	CbGeAlD
Pazopanib—TAOK3—female gonad—ovarian cancer	0.000364	0.00213	CbGeAlD
Pazopanib—STK10—vagina—ovarian cancer	0.000363	0.00212	CbGeAlD
Pazopanib—TAOK3—vagina—ovarian cancer	0.000362	0.00211	CbGeAlD
Pazopanib—PI4KB—lymph node—ovarian cancer	0.000362	0.00211	CbGeAlD
Pazopanib—PDGFRA—female gonad—ovarian cancer	0.000362	0.00211	CbGeAlD
Pazopanib—PDGFRA—vagina—ovarian cancer	0.00036	0.0021	CbGeAlD
Pazopanib—KDR—female reproductive system—ovarian cancer	0.000359	0.0021	CbGeAlD
Pazopanib—MAP2K5—female reproductive system—ovarian cancer	0.000359	0.0021	CbGeAlD
Pazopanib—KIT—gonad—ovarian cancer	0.000356	0.00208	CbGeAlD
Pazopanib—LIMK2—lymph node—ovarian cancer	0.000355	0.00208	CbGeAlD
Pazopanib—KIT—uterus—ovarian cancer	0.000354	0.00207	CbGeAlD
Pazopanib—CSF1R—female reproductive system—ovarian cancer	0.00035	0.00205	CbGeAlD
Pazopanib—PDGFRB—gonad—ovarian cancer	0.000348	0.00203	CbGeAlD
Pazopanib—PDGFRB—uterus—ovarian cancer	0.000345	0.00202	CbGeAlD
Pazopanib—FLT1—testis—ovarian cancer	0.000342	0.002	CbGeAlD
Pazopanib—KDR—bone marrow—ovarian cancer	0.000339	0.00198	CbGeAlD
Pazopanib—EPHB6—testis—ovarian cancer	0.000338	0.00198	CbGeAlD
Pazopanib—CSF1R—bone marrow—ovarian cancer	0.00033	0.00193	CbGeAlD
Pazopanib—KDR—female gonad—ovarian cancer	0.000326	0.00191	CbGeAlD
Pazopanib—MAP2K5—female gonad—ovarian cancer	0.000326	0.00191	CbGeAlD
Pazopanib—KDR—vagina—ovarian cancer	0.000324	0.0019	CbGeAlD
Pazopanib—MAP2K5—vagina—ovarian cancer	0.000324	0.0019	CbGeAlD
Pazopanib—STK10—testis—ovarian cancer	0.000324	0.00189	CbGeAlD
Pazopanib—TAOK3—testis—ovarian cancer	0.000323	0.00189	CbGeAlD
Pazopanib—PDGFRA—testis—ovarian cancer	0.000321	0.00188	CbGeAlD
Pazopanib—FLT4—lymph node—ovarian cancer	0.000319	0.00187	CbGeAlD
Pazopanib—CSF1R—female gonad—ovarian cancer	0.000319	0.00186	CbGeAlD
Pazopanib—KIT—female reproductive system—ovarian cancer	0.000318	0.00186	CbGeAlD
Pazopanib—PIP4K2C—lymph node—ovarian cancer	0.000317	0.00186	CbGeAlD
Pazopanib—CSF1R—vagina—ovarian cancer	0.000317	0.00185	CbGeAlD
Pazopanib—SLCO1B1—female reproductive system—ovarian cancer	0.000316	0.00184	CbGeAlD
Pazopanib—FGFR1—lymph node—ovarian cancer	0.000315	0.00184	CbGeAlD
Pazopanib—PDGFRB—female reproductive system—ovarian cancer	0.00031	0.00181	CbGeAlD
Pazopanib—MAP3K2—lymph node—ovarian cancer	0.000301	0.00176	CbGeAlD
Pazopanib—KIT—bone marrow—ovarian cancer	0.0003	0.00175	CbGeAlD
Pazopanib—ABCG2—myometrium—ovarian cancer	0.000299	0.00175	CbGeAlD
Pazopanib—PDGFRB—bone marrow—ovarian cancer	0.000293	0.00171	CbGeAlD
Pazopanib—KDR—testis—ovarian cancer	0.000289	0.00169	CbGeAlD
Pazopanib—MAP2K5—testis—ovarian cancer	0.000289	0.00169	CbGeAlD
Pazopanib—KIT—female gonad—ovarian cancer	0.000289	0.00169	CbGeAlD
Pazopanib—KIT—vagina—ovarian cancer	0.000287	0.00168	CbGeAlD
Pazopanib—FGF1—lymph node—ovarian cancer	0.000284	0.00166	CbGeAlD
Pazopanib—CSF1R—testis—ovarian cancer	0.000282	0.00165	CbGeAlD
Pazopanib—PDGFRB—female gonad—ovarian cancer	0.000282	0.00165	CbGeAlD
Pazopanib—LCK—lymph node—ovarian cancer	0.000282	0.00165	CbGeAlD
Pazopanib—PDGFRB—vagina—ovarian cancer	0.000281	0.00164	CbGeAlD
Pazopanib—KIT—testis—ovarian cancer	0.000257	0.0015	CbGeAlD
Pazopanib—PDGFRB—testis—ovarian cancer	0.000251	0.00146	CbGeAlD
Pazopanib—FLT1—lymph node—ovarian cancer	0.000248	0.00145	CbGeAlD
Pazopanib—EPHB6—lymph node—ovarian cancer	0.000245	0.00143	CbGeAlD
Pazopanib—STK10—lymph node—ovarian cancer	0.000235	0.00137	CbGeAlD
Pazopanib—TAOK3—lymph node—ovarian cancer	0.000234	0.00137	CbGeAlD
Pazopanib—ABCG2—uterine cervix—ovarian cancer	0.000233	0.00136	CbGeAlD
Pazopanib—PDGFRA—lymph node—ovarian cancer	0.000233	0.00136	CbGeAlD
Pazopanib—ABCG2—decidua—ovarian cancer	0.000222	0.0013	CbGeAlD
Pazopanib—CYP2C8—endometrium—ovarian cancer	0.000217	0.00127	CbGeAlD
Pazopanib—ABCG2—endometrium—ovarian cancer	0.000211	0.00123	CbGeAlD
Pazopanib—KDR—lymph node—ovarian cancer	0.00021	0.00123	CbGeAlD
Pazopanib—MAP2K5—lymph node—ovarian cancer	0.00021	0.00123	CbGeAlD
Pazopanib—CSF1R—lymph node—ovarian cancer	0.000205	0.0012	CbGeAlD
Pazopanib—ABCG2—uterus—ovarian cancer	0.000194	0.00113	CbGeAlD
Pazopanib—KIT—lymph node—ovarian cancer	0.000186	0.00109	CbGeAlD
Pazopanib—PDGFRB—lymph node—ovarian cancer	0.000182	0.00106	CbGeAlD
Pazopanib—CYP2C8—female reproductive system—ovarian cancer	0.000179	0.00105	CbGeAlD
Pazopanib—ABCG2—bone marrow—ovarian cancer	0.000165	0.000963	CbGeAlD
Pazopanib—CYP2C8—vagina—ovarian cancer	0.000162	0.000948	CbGeAlD
Pazopanib—ABCG2—female gonad—ovarian cancer	0.000159	0.000928	CbGeAlD
Pazopanib—ABCG2—vagina—ovarian cancer	0.000158	0.000922	CbGeAlD
Pazopanib—ABCB1—myometrium—ovarian cancer	0.000148	0.000862	CbGeAlD
Pazopanib—CYP2C8—testis—ovarian cancer	0.000145	0.000846	CbGeAlD
Pazopanib—ABCB1—embryo—ovarian cancer	0.000142	0.000829	CbGeAlD
Pazopanib—ABCG2—testis—ovarian cancer	0.000141	0.000823	CbGeAlD
Pazopanib—Pruritus—Vinorelbine—ovarian cancer	0.000126	0.000622	CcSEcCtD
Pazopanib—Breast disorder—Epirubicin—ovarian cancer	0.000126	0.000622	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000126	0.00062	CcSEcCtD
Pazopanib—Mental disorder—Docetaxel—ovarian cancer	0.000125	0.000618	CcSEcCtD
Pazopanib—Myalgia—Paclitaxel—ovarian cancer	0.000125	0.000617	CcSEcCtD
Pazopanib—Arthralgia—Paclitaxel—ovarian cancer	0.000125	0.000617	CcSEcCtD
Pazopanib—Chest pain—Paclitaxel—ovarian cancer	0.000125	0.000617	CcSEcCtD
Pazopanib—Nasopharyngitis—Epirubicin—ovarian cancer	0.000125	0.000615	CcSEcCtD
Pazopanib—Face oedema—Doxorubicin—ovarian cancer	0.000125	0.000615	CcSEcCtD
Pazopanib—Malnutrition—Docetaxel—ovarian cancer	0.000125	0.000614	CcSEcCtD
Pazopanib—Erythema—Docetaxel—ovarian cancer	0.000125	0.000614	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000124	0.000613	CcSEcCtD
Pazopanib—Nausea—Topotecan—ovarian cancer	0.000124	0.000611	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000123	0.000607	CcSEcCtD
Pazopanib—Dry mouth—Paclitaxel—ovarian cancer	0.000122	0.000604	CcSEcCtD
Pazopanib—Diarrhoea—Vinorelbine—ovarian cancer	0.000122	0.000602	CcSEcCtD
Pazopanib—Dysgeusia—Docetaxel—ovarian cancer	0.000122	0.000602	CcSEcCtD
Pazopanib—CYP3A4—female reproductive system—ovarian cancer	0.000122	0.00071	CbGeAlD
Pazopanib—Abdominal distension—Epirubicin—ovarian cancer	0.000121	0.000599	CcSEcCtD
Pazopanib—Nausea—Melphalan—ovarian cancer	0.000121	0.000598	CcSEcCtD
Pazopanib—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000121	0.000596	CcSEcCtD
Pazopanib—Dehydration—Doxorubicin—ovarian cancer	0.00012	0.000592	CcSEcCtD
Pazopanib—Oedema—Paclitaxel—ovarian cancer	0.00012	0.000592	CcSEcCtD
Pazopanib—Muscle spasms—Docetaxel—ovarian cancer	0.00012	0.000591	CcSEcCtD
Pazopanib—CYP2D6—female reproductive system—ovarian cancer	0.00012	0.000699	CbGeAlD
Pazopanib—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000119	0.000588	CcSEcCtD
Pazopanib—Infection—Paclitaxel—ovarian cancer	0.000119	0.000588	CcSEcCtD
Pazopanib—Dry skin—Doxorubicin—ovarian cancer	0.000118	0.000584	CcSEcCtD
Pazopanib—Pancreatitis—Epirubicin—ovarian cancer	0.000118	0.000583	CcSEcCtD
Pazopanib—Shock—Paclitaxel—ovarian cancer	0.000118	0.000582	CcSEcCtD
Pazopanib—Dizziness—Vinorelbine—ovarian cancer	0.000118	0.000582	CcSEcCtD
Pazopanib—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000118	0.000582	CcSEcCtD
Pazopanib—Nervous system disorder—Paclitaxel—ovarian cancer	0.000118	0.00058	CcSEcCtD
Pazopanib—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000117	0.000579	CcSEcCtD
Pazopanib—Breast disorder—Doxorubicin—ovarian cancer	0.000117	0.000575	CcSEcCtD
Pazopanib—Skin disorder—Paclitaxel—ovarian cancer	0.000117	0.000575	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000116	0.000573	CcSEcCtD
Pazopanib—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000116	0.000572	CcSEcCtD
Pazopanib—ABCB1—epithelium—ovarian cancer	0.000116	0.000677	CbGeAlD
Pazopanib—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000115	0.000569	CcSEcCtD
Pazopanib—Anaemia—Docetaxel—ovarian cancer	0.000115	0.000568	CcSEcCtD
Pazopanib—ABCB1—uterine cervix—ovarian cancer	0.000115	0.000671	CbGeAlD
Pazopanib—Anorexia—Paclitaxel—ovarian cancer	0.000114	0.000564	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000114	0.000562	CcSEcCtD
Pazopanib—Vomiting—Vinorelbine—ovarian cancer	0.000113	0.000559	CcSEcCtD
Pazopanib—Neutropenia—Epirubicin—ovarian cancer	0.000113	0.000556	CcSEcCtD
Pazopanib—Rash—Vinorelbine—ovarian cancer	0.000112	0.000555	CcSEcCtD
Pazopanib—Dermatitis—Vinorelbine—ovarian cancer	0.000112	0.000554	CcSEcCtD
Pazopanib—Abdominal distension—Doxorubicin—ovarian cancer	0.000112	0.000554	CcSEcCtD
Pazopanib—Headache—Vinorelbine—ovarian cancer	0.000112	0.000551	CcSEcCtD
Pazopanib—Syncope—Docetaxel—ovarian cancer	0.000112	0.000551	CcSEcCtD
Pazopanib—Leukopenia—Docetaxel—ovarian cancer	0.000112	0.00055	CcSEcCtD
Pazopanib—Photosensitivity reaction—Epirubicin—ovarian cancer	0.00011	0.000543	CcSEcCtD
Pazopanib—Loss of consciousness—Docetaxel—ovarian cancer	0.000109	0.00054	CcSEcCtD
Pazopanib—ABCB1—decidua—ovarian cancer	0.000109	0.000639	CbGeAlD
Pazopanib—Pancreatitis—Doxorubicin—ovarian cancer	0.000109	0.00054	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000109	0.000539	CcSEcCtD
Pazopanib—Weight decreased—Epirubicin—ovarian cancer	0.000109	0.000538	CcSEcCtD
Pazopanib—CYP2D6—female gonad—ovarian cancer	0.000109	0.000636	CbGeAlD
Pazopanib—Cough—Docetaxel—ovarian cancer	0.000109	0.000536	CcSEcCtD
Pazopanib—Insomnia—Paclitaxel—ovarian cancer	0.000108	0.000535	CcSEcCtD
Pazopanib—Paraesthesia—Paclitaxel—ovarian cancer	0.000108	0.000531	CcSEcCtD
Pazopanib—Hypertension—Docetaxel—ovarian cancer	0.000108	0.00053	CcSEcCtD
Pazopanib—Infestation—Epirubicin—ovarian cancer	0.000108	0.00053	CcSEcCtD
Pazopanib—Infestation NOS—Epirubicin—ovarian cancer	0.000108	0.00053	CcSEcCtD
Pazopanib—Dyspnoea—Paclitaxel—ovarian cancer	0.000107	0.000527	CcSEcCtD
Pazopanib—Somnolence—Paclitaxel—ovarian cancer	0.000107	0.000526	CcSEcCtD
Pazopanib—Arthralgia—Docetaxel—ovarian cancer	0.000106	0.000523	CcSEcCtD
Pazopanib—Chest pain—Docetaxel—ovarian cancer	0.000106	0.000523	CcSEcCtD
Pazopanib—Myalgia—Docetaxel—ovarian cancer	0.000106	0.000523	CcSEcCtD
Pazopanib—Nausea—Vinorelbine—ovarian cancer	0.000106	0.000522	CcSEcCtD
Pazopanib—Dyspepsia—Paclitaxel—ovarian cancer	0.000106	0.000521	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000105	0.000519	CcSEcCtD
Pazopanib—Jaundice—Epirubicin—ovarian cancer	0.000105	0.000517	CcSEcCtD
Pazopanib—Stomatitis—Epirubicin—ovarian cancer	0.000105	0.000517	CcSEcCtD
Pazopanib—Neutropenia—Doxorubicin—ovarian cancer	0.000104	0.000515	CcSEcCtD
Pazopanib—Decreased appetite—Paclitaxel—ovarian cancer	0.000104	0.000514	CcSEcCtD
Pazopanib—ABCB1—endometrium—ovarian cancer	0.000104	0.000607	CbGeAlD
Pazopanib—Dry mouth—Docetaxel—ovarian cancer	0.000104	0.000512	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000104	0.000511	CcSEcCtD
Pazopanib—Fatigue—Paclitaxel—ovarian cancer	0.000103	0.00051	CcSEcCtD
Pazopanib—Pain—Paclitaxel—ovarian cancer	0.000103	0.000506	CcSEcCtD
Pazopanib—Haematuria—Epirubicin—ovarian cancer	0.000103	0.000506	CcSEcCtD
Pazopanib—ABCG2—lymph node—ovarian cancer	0.000102	0.000596	CbGeAlD
Pazopanib—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000102	0.000502	CcSEcCtD
Pazopanib—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000102	0.000502	CcSEcCtD
Pazopanib—Oedema—Docetaxel—ovarian cancer	0.000102	0.000501	CcSEcCtD
Pazopanib—Epistaxis—Epirubicin—ovarian cancer	0.000101	0.0005	CcSEcCtD
Pazopanib—Infection—Docetaxel—ovarian cancer	0.000101	0.000498	CcSEcCtD
Pazopanib—Weight decreased—Doxorubicin—ovarian cancer	0.000101	0.000498	CcSEcCtD
Pazopanib—Shock—Docetaxel—ovarian cancer	0.0001	0.000493	CcSEcCtD
Pazopanib—Nervous system disorder—Docetaxel—ovarian cancer	9.97e-05	0.000492	CcSEcCtD
Pazopanib—Thrombocytopenia—Docetaxel—ovarian cancer	9.96e-05	0.000491	CcSEcCtD
Pazopanib—Infestation—Doxorubicin—ovarian cancer	9.95e-05	0.000491	CcSEcCtD
Pazopanib—Infestation NOS—Doxorubicin—ovarian cancer	9.95e-05	0.000491	CcSEcCtD
Pazopanib—Skin disorder—Docetaxel—ovarian cancer	9.88e-05	0.000487	CcSEcCtD
Pazopanib—Bradycardia—Epirubicin—ovarian cancer	9.83e-05	0.000485	CcSEcCtD
Pazopanib—Gastrointestinal pain—Paclitaxel—ovarian cancer	9.81e-05	0.000484	CcSEcCtD
Pazopanib—Haemoglobin—Epirubicin—ovarian cancer	9.7e-05	0.000478	CcSEcCtD
Pazopanib—Jaundice—Doxorubicin—ovarian cancer	9.7e-05	0.000478	CcSEcCtD
Pazopanib—Stomatitis—Doxorubicin—ovarian cancer	9.7e-05	0.000478	CcSEcCtD
Pazopanib—Anorexia—Docetaxel—ovarian cancer	9.69e-05	0.000478	CcSEcCtD
Pazopanib—CYP2D6—testis—ovarian cancer	9.65e-05	0.000564	CbGeAlD
Pazopanib—Haemorrhage—Epirubicin—ovarian cancer	9.65e-05	0.000476	CcSEcCtD
Pazopanib—ABCB1—gonad—ovarian cancer	9.63e-05	0.000563	CbGeAlD
Pazopanib—Hypoaesthesia—Epirubicin—ovarian cancer	9.6e-05	0.000474	CcSEcCtD
Pazopanib—ABCB1—uterus—ovarian cancer	9.57e-05	0.000559	CbGeAlD
Pazopanib—Urinary tract disorder—Epirubicin—ovarian cancer	9.53e-05	0.00047	CcSEcCtD
Pazopanib—Oedema peripheral—Epirubicin—ovarian cancer	9.51e-05	0.000469	CcSEcCtD
Pazopanib—Haematuria—Doxorubicin—ovarian cancer	9.49e-05	0.000468	CcSEcCtD
Pazopanib—Connective tissue disorder—Epirubicin—ovarian cancer	9.49e-05	0.000468	CcSEcCtD
Pazopanib—Abdominal pain—Paclitaxel—ovarian cancer	9.48e-05	0.000468	CcSEcCtD
Pazopanib—Urethral disorder—Epirubicin—ovarian cancer	9.46e-05	0.000467	CcSEcCtD
Pazopanib—Hepatobiliary disease—Doxorubicin—ovarian cancer	9.41e-05	0.000464	CcSEcCtD
Pazopanib—Epistaxis—Doxorubicin—ovarian cancer	9.38e-05	0.000463	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	9.26e-05	0.000457	CcSEcCtD
Pazopanib—Insomnia—Docetaxel—ovarian cancer	9.2e-05	0.000454	CcSEcCtD
Pazopanib—Paraesthesia—Docetaxel—ovarian cancer	9.13e-05	0.00045	CcSEcCtD
Pazopanib—Bradycardia—Doxorubicin—ovarian cancer	9.09e-05	0.000448	CcSEcCtD
Pazopanib—Dyspnoea—Docetaxel—ovarian cancer	9.06e-05	0.000447	CcSEcCtD
Pazopanib—Somnolence—Docetaxel—ovarian cancer	9.04e-05	0.000446	CcSEcCtD
Pazopanib—Eye disorder—Epirubicin—ovarian cancer	9.02e-05	0.000445	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—ovarian cancer	8.98e-05	0.000443	CcSEcCtD
Pazopanib—Cardiac disorder—Epirubicin—ovarian cancer	8.96e-05	0.000442	CcSEcCtD
Pazopanib—Flushing—Epirubicin—ovarian cancer	8.96e-05	0.000442	CcSEcCtD
Pazopanib—Dyspepsia—Docetaxel—ovarian cancer	8.95e-05	0.000441	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—ovarian cancer	8.93e-05	0.00044	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—ovarian cancer	8.89e-05	0.000438	CcSEcCtD
Pazopanib—Decreased appetite—Docetaxel—ovarian cancer	8.84e-05	0.000436	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—ovarian cancer	8.82e-05	0.000435	CcSEcCtD
Pazopanib—Oedema peripheral—Doxorubicin—ovarian cancer	8.8e-05	0.000434	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Docetaxel—ovarian cancer	8.78e-05	0.000433	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—ovarian cancer	8.78e-05	0.000433	CcSEcCtD
Pazopanib—Fatigue—Docetaxel—ovarian cancer	8.77e-05	0.000432	CcSEcCtD
Pazopanib—Angiopathy—Epirubicin—ovarian cancer	8.76e-05	0.000432	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—ovarian cancer	8.76e-05	0.000432	CcSEcCtD
Pazopanib—Mediastinal disorder—Epirubicin—ovarian cancer	8.7e-05	0.000429	CcSEcCtD
Pazopanib—Pain—Docetaxel—ovarian cancer	8.69e-05	0.000429	CcSEcCtD
Pazopanib—Chills—Epirubicin—ovarian cancer	8.66e-05	0.000427	CcSEcCtD
Pazopanib—Asthenia—Paclitaxel—ovarian cancer	8.61e-05	0.000424	CcSEcCtD
Pazopanib—ABCB1—female reproductive system—ovarian cancer	8.6e-05	0.000503	CbGeAlD
Pazopanib—Alopecia—Epirubicin—ovarian cancer	8.53e-05	0.000421	CcSEcCtD
Pazopanib—Pruritus—Paclitaxel—ovarian cancer	8.49e-05	0.000419	CcSEcCtD
Pazopanib—Mental disorder—Epirubicin—ovarian cancer	8.46e-05	0.000417	CcSEcCtD
Pazopanib—Malnutrition—Epirubicin—ovarian cancer	8.4e-05	0.000414	CcSEcCtD
Pazopanib—Erythema—Epirubicin—ovarian cancer	8.4e-05	0.000414	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—ovarian cancer	8.35e-05	0.000412	CcSEcCtD
Pazopanib—Gastrointestinal pain—Docetaxel—ovarian cancer	8.31e-05	0.00041	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—ovarian cancer	8.29e-05	0.000409	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—ovarian cancer	8.29e-05	0.000409	CcSEcCtD
Pazopanib—Flatulence—Epirubicin—ovarian cancer	8.28e-05	0.000408	CcSEcCtD
Pazopanib—Dysgeusia—Epirubicin—ovarian cancer	8.23e-05	0.000406	CcSEcCtD
Pazopanib—Diarrhoea—Paclitaxel—ovarian cancer	8.21e-05	0.000405	CcSEcCtD
Pazopanib—ABCB1—bone marrow—ovarian cancer	8.12e-05	0.000475	CbGeAlD
Pazopanib—Angiopathy—Doxorubicin—ovarian cancer	8.1e-05	0.0004	CcSEcCtD
Pazopanib—Muscle spasms—Epirubicin—ovarian cancer	8.08e-05	0.000398	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—ovarian cancer	8.05e-05	0.000397	CcSEcCtD
Pazopanib—Abdominal pain—Docetaxel—ovarian cancer	8.04e-05	0.000396	CcSEcCtD
Pazopanib—Chills—Doxorubicin—ovarian cancer	8.01e-05	0.000395	CcSEcCtD
Pazopanib—Dizziness—Paclitaxel—ovarian cancer	7.93e-05	0.000391	CcSEcCtD
Pazopanib—Vision blurred—Epirubicin—ovarian cancer	7.92e-05	0.000391	CcSEcCtD
Pazopanib—Alopecia—Doxorubicin—ovarian cancer	7.89e-05	0.000389	CcSEcCtD
Pazopanib—ABCB1—female gonad—ovarian cancer	7.83e-05	0.000458	CbGeAlD
Pazopanib—Mental disorder—Doxorubicin—ovarian cancer	7.82e-05	0.000386	CcSEcCtD
Pazopanib—ABCB1—vagina—ovarian cancer	7.78e-05	0.000455	CbGeAlD
Pazopanib—Malnutrition—Doxorubicin—ovarian cancer	7.78e-05	0.000383	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—ovarian cancer	7.78e-05	0.000383	CcSEcCtD
Pazopanib—Anaemia—Epirubicin—ovarian cancer	7.77e-05	0.000383	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—ovarian cancer	7.66e-05	0.000378	CcSEcCtD
Pazopanib—Vomiting—Paclitaxel—ovarian cancer	7.63e-05	0.000376	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—ovarian cancer	7.61e-05	0.000375	CcSEcCtD
Pazopanib—Rash—Paclitaxel—ovarian cancer	7.56e-05	0.000373	CcSEcCtD
Pazopanib—Dermatitis—Paclitaxel—ovarian cancer	7.56e-05	0.000373	CcSEcCtD
Pazopanib—Syncope—Epirubicin—ovarian cancer	7.54e-05	0.000372	CcSEcCtD
Pazopanib—Leukopenia—Epirubicin—ovarian cancer	7.52e-05	0.000371	CcSEcCtD
Pazopanib—Headache—Paclitaxel—ovarian cancer	7.51e-05	0.000371	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—ovarian cancer	7.48e-05	0.000369	CcSEcCtD
Pazopanib—Loss of consciousness—Epirubicin—ovarian cancer	7.39e-05	0.000364	CcSEcCtD
Pazopanib—Cough—Epirubicin—ovarian cancer	7.33e-05	0.000362	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—ovarian cancer	7.33e-05	0.000361	CcSEcCtD
Pazopanib—Asthenia—Docetaxel—ovarian cancer	7.29e-05	0.00036	CcSEcCtD
Pazopanib—Hypertension—Epirubicin—ovarian cancer	7.25e-05	0.000358	CcSEcCtD
Pazopanib—Pruritus—Docetaxel—ovarian cancer	7.19e-05	0.000355	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—ovarian cancer	7.19e-05	0.000354	CcSEcCtD
Pazopanib—Arthralgia—Epirubicin—ovarian cancer	7.15e-05	0.000353	CcSEcCtD
Pazopanib—Chest pain—Epirubicin—ovarian cancer	7.15e-05	0.000353	CcSEcCtD
Pazopanib—Myalgia—Epirubicin—ovarian cancer	7.15e-05	0.000353	CcSEcCtD
Pazopanib—Nausea—Paclitaxel—ovarian cancer	7.13e-05	0.000351	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	7.1e-05	0.00035	CcSEcCtD
Pazopanib—Dry mouth—Epirubicin—ovarian cancer	7e-05	0.000345	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—ovarian cancer	6.97e-05	0.000344	CcSEcCtD
Pazopanib—Leukopenia—Doxorubicin—ovarian cancer	6.96e-05	0.000343	CcSEcCtD
Pazopanib—Diarrhoea—Docetaxel—ovarian cancer	6.96e-05	0.000343	CcSEcCtD
Pazopanib—ABCB1—testis—ovarian cancer	6.94e-05	0.000406	CbGeAlD
Pazopanib—Oedema—Epirubicin—ovarian cancer	6.86e-05	0.000338	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—ovarian cancer	6.83e-05	0.000337	CcSEcCtD
Pazopanib—Infection—Epirubicin—ovarian cancer	6.81e-05	0.000336	CcSEcCtD
Pazopanib—Cough—Doxorubicin—ovarian cancer	6.78e-05	0.000335	CcSEcCtD
Pazopanib—Shock—Epirubicin—ovarian cancer	6.75e-05	0.000333	CcSEcCtD
Pazopanib—Nervous system disorder—Epirubicin—ovarian cancer	6.73e-05	0.000332	CcSEcCtD
Pazopanib—Dizziness—Docetaxel—ovarian cancer	6.72e-05	0.000332	CcSEcCtD
Pazopanib—Thrombocytopenia—Epirubicin—ovarian cancer	6.71e-05	0.000331	CcSEcCtD
Pazopanib—Hypertension—Doxorubicin—ovarian cancer	6.71e-05	0.000331	CcSEcCtD
Pazopanib—Skin disorder—Epirubicin—ovarian cancer	6.66e-05	0.000329	CcSEcCtD
Pazopanib—Hyperhidrosis—Epirubicin—ovarian cancer	6.63e-05	0.000327	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—ovarian cancer	6.62e-05	0.000326	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—ovarian cancer	6.62e-05	0.000326	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—ovarian cancer	6.62e-05	0.000326	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	6.57e-05	0.000324	CcSEcCtD
Pazopanib—Anorexia—Epirubicin—ovarian cancer	6.54e-05	0.000322	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—ovarian cancer	6.47e-05	0.000319	CcSEcCtD
Pazopanib—Vomiting—Docetaxel—ovarian cancer	6.46e-05	0.000319	CcSEcCtD
Pazopanib—Rash—Docetaxel—ovarian cancer	6.41e-05	0.000316	CcSEcCtD
Pazopanib—Dermatitis—Docetaxel—ovarian cancer	6.4e-05	0.000316	CcSEcCtD
Pazopanib—Headache—Docetaxel—ovarian cancer	6.37e-05	0.000314	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—ovarian cancer	6.35e-05	0.000313	CcSEcCtD
Pazopanib—Infection—Doxorubicin—ovarian cancer	6.3e-05	0.000311	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	6.25e-05	0.000308	CcSEcCtD
Pazopanib—Shock—Doxorubicin—ovarian cancer	6.24e-05	0.000308	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—ovarian cancer	6.22e-05	0.000307	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—ovarian cancer	6.21e-05	0.000306	CcSEcCtD
Pazopanib—Insomnia—Epirubicin—ovarian cancer	6.2e-05	0.000306	CcSEcCtD
Pazopanib—Skin disorder—Doxorubicin—ovarian cancer	6.16e-05	0.000304	CcSEcCtD
Pazopanib—Paraesthesia—Epirubicin—ovarian cancer	6.16e-05	0.000304	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—ovarian cancer	6.13e-05	0.000303	CcSEcCtD
Pazopanib—Dyspnoea—Epirubicin—ovarian cancer	6.11e-05	0.000302	CcSEcCtD
Pazopanib—Somnolence—Epirubicin—ovarian cancer	6.1e-05	0.000301	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—ovarian cancer	6.05e-05	0.000298	CcSEcCtD
Pazopanib—Nausea—Docetaxel—ovarian cancer	6.04e-05	0.000298	CcSEcCtD
Pazopanib—Dyspepsia—Epirubicin—ovarian cancer	6.04e-05	0.000298	CcSEcCtD
Pazopanib—Decreased appetite—Epirubicin—ovarian cancer	5.96e-05	0.000294	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Epirubicin—ovarian cancer	5.92e-05	0.000292	CcSEcCtD
Pazopanib—Fatigue—Epirubicin—ovarian cancer	5.91e-05	0.000292	CcSEcCtD
Pazopanib—Pain—Epirubicin—ovarian cancer	5.86e-05	0.000289	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	5.78e-05	0.000285	CcSEcCtD
Pazopanib—Insomnia—Doxorubicin—ovarian cancer	5.74e-05	0.000283	CcSEcCtD
Pazopanib—Paraesthesia—Doxorubicin—ovarian cancer	5.7e-05	0.000281	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—ovarian cancer	5.66e-05	0.000279	CcSEcCtD
Pazopanib—Somnolence—Doxorubicin—ovarian cancer	5.64e-05	0.000278	CcSEcCtD
Pazopanib—Gastrointestinal pain—Epirubicin—ovarian cancer	5.61e-05	0.000277	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—ovarian cancer	5.59e-05	0.000275	CcSEcCtD
Pazopanib—Decreased appetite—Doxorubicin—ovarian cancer	5.52e-05	0.000272	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	5.48e-05	0.00027	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—ovarian cancer	5.47e-05	0.00027	CcSEcCtD
Pazopanib—Pain—Doxorubicin—ovarian cancer	5.43e-05	0.000268	CcSEcCtD
Pazopanib—Abdominal pain—Epirubicin—ovarian cancer	5.42e-05	0.000267	CcSEcCtD
Pazopanib—Gastrointestinal pain—Doxorubicin—ovarian cancer	5.19e-05	0.000256	CcSEcCtD
Pazopanib—ABCB1—lymph node—ovarian cancer	5.03e-05	0.000294	CbGeAlD
Pazopanib—Abdominal pain—Doxorubicin—ovarian cancer	5.02e-05	0.000247	CcSEcCtD
Pazopanib—Asthenia—Epirubicin—ovarian cancer	4.92e-05	0.000243	CcSEcCtD
Pazopanib—Pruritus—Epirubicin—ovarian cancer	4.85e-05	0.000239	CcSEcCtD
Pazopanib—Diarrhoea—Epirubicin—ovarian cancer	4.69e-05	0.000231	CcSEcCtD
Pazopanib—Asthenia—Doxorubicin—ovarian cancer	4.55e-05	0.000225	CcSEcCtD
Pazopanib—Dizziness—Epirubicin—ovarian cancer	4.54e-05	0.000224	CcSEcCtD
Pazopanib—Pruritus—Doxorubicin—ovarian cancer	4.49e-05	0.000221	CcSEcCtD
Pazopanib—Vomiting—Epirubicin—ovarian cancer	4.36e-05	0.000215	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—ovarian cancer	4.34e-05	0.000214	CcSEcCtD
Pazopanib—Rash—Epirubicin—ovarian cancer	4.32e-05	0.000213	CcSEcCtD
Pazopanib—Dermatitis—Epirubicin—ovarian cancer	4.32e-05	0.000213	CcSEcCtD
Pazopanib—Headache—Epirubicin—ovarian cancer	4.3e-05	0.000212	CcSEcCtD
Pazopanib—Dizziness—Doxorubicin—ovarian cancer	4.2e-05	0.000207	CcSEcCtD
Pazopanib—Nausea—Epirubicin—ovarian cancer	4.07e-05	0.000201	CcSEcCtD
Pazopanib—Vomiting—Doxorubicin—ovarian cancer	4.03e-05	0.000199	CcSEcCtD
Pazopanib—Rash—Doxorubicin—ovarian cancer	4e-05	0.000197	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—ovarian cancer	4e-05	0.000197	CcSEcCtD
Pazopanib—Headache—Doxorubicin—ovarian cancer	3.98e-05	0.000196	CcSEcCtD
Pazopanib—Nausea—Doxorubicin—ovarian cancer	3.77e-05	0.000186	CcSEcCtD
Pazopanib—PDGFRB—Disease—KRAS—ovarian cancer	2.49e-06	1.05e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTEN—ovarian cancer	2.49e-06	1.05e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—PIK3CA—ovarian cancer	2.48e-06	1.05e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—HRAS—ovarian cancer	2.48e-06	1.05e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—PIK3CA—ovarian cancer	2.48e-06	1.05e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CXCL8—ovarian cancer	2.47e-06	1.04e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CDKN1B—ovarian cancer	2.46e-06	1.04e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IL6—ovarian cancer	2.46e-06	1.04e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—VEGFA—ovarian cancer	2.45e-06	1.03e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CB—ovarian cancer	2.44e-06	1.03e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL6—ovarian cancer	2.44e-06	1.03e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL6—ovarian cancer	2.43e-06	1.03e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	2.43e-06	1.02e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—PIK3CA—ovarian cancer	2.42e-06	1.02e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—STAT3—ovarian cancer	2.42e-06	1.02e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—PIK3CA—ovarian cancer	2.42e-06	1.02e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CD—ovarian cancer	2.42e-06	1.02e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—NRAS—ovarian cancer	2.42e-06	1.02e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—IL6—ovarian cancer	2.42e-06	1.02e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—SLC2A1—ovarian cancer	2.42e-06	1.02e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CASP3—ovarian cancer	2.42e-06	1.02e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—AKT1—ovarian cancer	2.41e-06	1.02e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CDKN1B—ovarian cancer	2.41e-06	1.02e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL2—ovarian cancer	2.41e-06	1.02e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—YAP1—ovarian cancer	2.41e-06	1.02e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—MAPK3—ovarian cancer	2.41e-06	1.02e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—VEGFA—ovarian cancer	2.4e-06	1.01e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—ovarian cancer	2.4e-06	1.01e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—STAT3—ovarian cancer	2.38e-06	1e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NRAS—ovarian cancer	2.37e-06	1e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—IL6—ovarian cancer	2.37e-06	1e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—AKT1—ovarian cancer	2.37e-06	1e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.37e-06	9.99e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CASP3—ovarian cancer	2.36e-06	9.98e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL2—ovarian cancer	2.36e-06	9.97e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HRAS—ovarian cancer	2.35e-06	9.94e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCND1—ovarian cancer	2.35e-06	9.93e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HRAS—ovarian cancer	2.35e-06	9.91e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—TYMS—ovarian cancer	2.35e-06	9.91e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—ovarian cancer	2.34e-06	9.89e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CTNNB1—ovarian cancer	2.33e-06	9.83e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—STAT3—ovarian cancer	2.33e-06	9.82e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—NRAS—ovarian cancer	2.32e-06	9.8e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP1B1—ovarian cancer	2.32e-06	9.78e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MAPK3—ovarian cancer	2.31e-06	9.77e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PIK3CA—ovarian cancer	2.31e-06	9.75e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCND1—ovarian cancer	2.3e-06	9.72e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—ovarian cancer	2.3e-06	9.7e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—ovarian cancer	2.29e-06	9.67e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—MAPK1—ovarian cancer	2.29e-06	9.67e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—EGFR—ovarian cancer	2.29e-06	9.67e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PIK3CA—ovarian cancer	2.29e-06	9.65e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MMP9—ovarian cancer	2.28e-06	9.64e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—ovarian cancer	2.28e-06	9.63e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CTNNB1—ovarian cancer	2.28e-06	9.62e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTEN—ovarian cancer	2.28e-06	9.62e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—ovarian cancer	2.27e-06	9.61e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MAPK3—ovarian cancer	2.27e-06	9.6e-06	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—AKT1—ovarian cancer	2.27e-06	9.59e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTEN—ovarian cancer	2.27e-06	9.58e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—STAT3—ovarian cancer	2.26e-06	9.54e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NRAS—ovarian cancer	2.25e-06	9.51e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—IL6—ovarian cancer	2.25e-06	9.51e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—STAT3—ovarian cancer	2.25e-06	9.51e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ABCB1—ovarian cancer	2.25e-06	9.51e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—ovarian cancer	2.25e-06	9.51e-06	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—AKT1—ovarian cancer	2.25e-06	9.5e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NRAS—ovarian cancer	2.25e-06	9.49e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—IL6—ovarian cancer	2.25e-06	9.49e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—AKT1—ovarian cancer	2.25e-06	9.48e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—ovarian cancer	2.24e-06	9.47e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—ovarian cancer	2.24e-06	9.46e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MMP9—ovarian cancer	2.23e-06	9.44e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—ovarian cancer	2.23e-06	9.43e-06	CbGpPWpGaD
Pazopanib—FGFR2—Disease—AKT1—ovarian cancer	2.23e-06	9.41e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MAPK3—ovarian cancer	2.22e-06	9.38e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTEN—ovarian cancer	2.22e-06	9.38e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—TYMS—ovarian cancer	2.21e-06	9.34e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—ovarian cancer	2.21e-06	9.34e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MAPK1—ovarian cancer	2.2e-06	9.3e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EGFR—ovarian cancer	2.2e-06	9.3e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL6—ovarian cancer	2.2e-06	9.29e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL6—ovarian cancer	2.19e-06	9.26e-06	CbGpPWpGaD
Pazopanib—KIT—Disease—AKT1—ovarian cancer	2.19e-06	9.25e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CAV1—ovarian cancer	2.17e-06	9.17e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MAPK1—ovarian cancer	2.16e-06	9.13e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EGFR—ovarian cancer	2.16e-06	9.13e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—ovarian cancer	2.16e-06	9.13e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—ovarian cancer	2.16e-06	9.12e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MAPK3—ovarian cancer	2.16e-06	9.11e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MAPK3—ovarian cancer	2.15e-06	9.09e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6—ovarian cancer	2.15e-06	9.06e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6—ovarian cancer	2.14e-06	9.05e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—ovarian cancer	2.14e-06	9.02e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB2—ovarian cancer	2.14e-06	9.02e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—ovarian cancer	2.11e-06	8.93e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MAPK1—ovarian cancer	2.11e-06	8.93e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—EGFR—ovarian cancer	2.11e-06	8.93e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTEN—ovarian cancer	2.11e-06	8.91e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MTOR—ovarian cancer	2.11e-06	8.9e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CB—ovarian cancer	2.11e-06	8.9e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—ovarian cancer	2.1e-06	8.86e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—ovarian cancer	2.09e-06	8.84e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—ovarian cancer	2.08e-06	8.78e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—AKT1—ovarian cancer	2.08e-06	8.78e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.07e-06	8.76e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—AKT1—ovarian cancer	2.07e-06	8.75e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	2.05e-06	8.68e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MAPK1—ovarian cancer	2.05e-06	8.67e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EGFR—ovarian cancer	2.05e-06	8.67e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—ovarian cancer	2.05e-06	8.65e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MAPK1—ovarian cancer	2.05e-06	8.65e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EGFR—ovarian cancer	2.05e-06	8.64e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6—ovarian cancer	2.04e-06	8.64e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.04e-06	8.63e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—ovarian cancer	2.04e-06	8.63e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—AKT1—ovarian cancer	2.03e-06	8.57e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—STAT3—ovarian cancer	2.03e-06	8.57e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CXCL8—ovarian cancer	2.03e-06	8.55e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NRAS—ovarian cancer	2.02e-06	8.55e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6—ovarian cancer	2.02e-06	8.55e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—AKT1—ovarian cancer	2.02e-06	8.54e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—ovarian cancer	2.01e-06	8.47e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—ovarian cancer	2e-06	8.43e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—PIK3CA—ovarian cancer	1.99e-06	8.39e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—STAT3—ovarian cancer	1.99e-06	8.39e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NRAS—ovarian cancer	1.98e-06	8.37e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—AKT1—ovarian cancer	1.98e-06	8.36e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1B—ovarian cancer	1.98e-06	8.35e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—AKT1—ovarian cancer	1.98e-06	8.35e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CG—ovarian cancer	1.98e-06	8.35e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—FASN—ovarian cancer	1.96e-06	8.29e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—ovarian cancer	1.94e-06	8.19e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAPK3—ovarian cancer	1.94e-06	8.19e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CASP3—ovarian cancer	1.94e-06	8.18e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL2—ovarian cancer	1.94e-06	8.17e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—ovarian cancer	1.93e-06	8.17e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.93e-06	8.15e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PIK3CA—ovarian cancer	1.91e-06	8.07e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ABCB1—ovarian cancer	1.91e-06	8.06e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAPK3—ovarian cancer	1.9e-06	8.02e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CAV1—ovarian cancer	1.89e-06	7.99e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—AKT1—ovarian cancer	1.89e-06	7.97e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—ovarian cancer	1.89e-06	7.97e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—ovarian cancer	1.89e-06	7.96e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PIK3CA—ovarian cancer	1.88e-06	7.93e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—TYMS—ovarian cancer	1.87e-06	7.91e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CTNNB1—ovarian cancer	1.87e-06	7.89e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—AKT1—ovarian cancer	1.87e-06	7.89e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.86e-06	7.87e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—ovarian cancer	1.85e-06	7.81e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—ovarian cancer	1.85e-06	7.8e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAPK1—ovarian cancer	1.84e-06	7.79e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EGFR—ovarian cancer	1.84e-06	7.79e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—ovarian cancer	1.84e-06	7.76e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—PIK3CA—ovarian cancer	1.83e-06	7.75e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MMP9—ovarian cancer	1.83e-06	7.73e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTEN—ovarian cancer	1.82e-06	7.69e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—ovarian cancer	1.82e-06	7.67e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAPK1—ovarian cancer	1.81e-06	7.63e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EGFR—ovarian cancer	1.81e-06	7.63e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.79e-06	7.55e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CAV1—ovarian cancer	1.78e-06	7.53e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PIK3CA—ovarian cancer	1.78e-06	7.52e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PIK3CA—ovarian cancer	1.78e-06	7.5e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—ovarian cancer	1.77e-06	7.47e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6—ovarian cancer	1.76e-06	7.43e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PIK3CA—ovarian cancer	1.75e-06	7.41e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—ovarian cancer	1.74e-06	7.36e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CD—ovarian cancer	1.74e-06	7.34e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—ovarian cancer	1.74e-06	7.33e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—ovarian cancer	1.72e-06	7.28e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.72e-06	7.27e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—ovarian cancer	1.72e-06	7.26e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—ovarian cancer	1.71e-06	7.2e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—ovarian cancer	1.7e-06	7.17e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6—ovarian cancer	1.69e-06	7.15e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6—ovarian cancer	1.66e-06	7.02e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—ovarian cancer	1.65e-06	6.96e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—ovarian cancer	1.64e-06	6.95e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—ovarian cancer	1.64e-06	6.94e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—STAT3—ovarian cancer	1.63e-06	6.88e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NRAS—ovarian cancer	1.62e-06	6.86e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6—ovarian cancer	1.62e-06	6.86e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.62e-06	6.85e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—AKT1—ovarian cancer	1.62e-06	6.85e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PIK3CA—ovarian cancer	1.61e-06	6.79e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PIK3CA—ovarian cancer	1.6e-06	6.76e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.59e-06	6.7e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6—ovarian cancer	1.58e-06	6.66e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6—ovarian cancer	1.57e-06	6.64e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PIK3CA—ovarian cancer	1.57e-06	6.62e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—AKT1—ovarian cancer	1.56e-06	6.59e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAPK3—ovarian cancer	1.56e-06	6.57e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—ovarian cancer	1.55e-06	6.54e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—AKT1—ovarian cancer	1.53e-06	6.47e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—ovarian cancer	1.52e-06	6.4e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CB—ovarian cancer	1.52e-06	6.4e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CD—ovarian cancer	1.51e-06	6.39e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—ovarian cancer	1.51e-06	6.39e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CAV1—ovarian cancer	1.51e-06	6.38e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—AKT1—ovarian cancer	1.5e-06	6.33e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CA—ovarian cancer	1.49e-06	6.28e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—ovarian cancer	1.48e-06	6.25e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAPK1—ovarian cancer	1.48e-06	6.25e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EGFR—ovarian cancer	1.48e-06	6.25e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.47e-06	6.22e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—AKT1—ovarian cancer	1.46e-06	6.15e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—AKT1—ovarian cancer	1.45e-06	6.13e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—ovarian cancer	1.45e-06	6.12e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TYMS—ovarian cancer	1.45e-06	6.11e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.44e-06	6.09e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AKT1—ovarian cancer	1.43e-06	6.05e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.43e-06	6.03e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6—ovarian cancer	1.42e-06	5.99e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—ovarian cancer	1.4e-06	5.9e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6—ovarian cancer	1.39e-06	5.86e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.38e-06	5.81e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.32e-06	5.57e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AKT1—ovarian cancer	1.31e-06	5.54e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTEN—ovarian cancer	1.31e-06	5.53e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—AKT1—ovarian cancer	1.31e-06	5.52e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CA—ovarian cancer	1.28e-06	5.42e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—AKT1—ovarian cancer	1.28e-06	5.41e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.24e-06	5.25e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—ovarian cancer	1.24e-06	5.25e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AKT1—ovarian cancer	1.22e-06	5.13e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.21e-06	5.1e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—ovarian cancer	1.19e-06	5.02e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CAV1—ovarian cancer	1.17e-06	4.92e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTEN—ovarian cancer	1.14e-06	4.82e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6—ovarian cancer	1.14e-06	4.8e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTEN—ovarian cancer	1.07e-06	4.54e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.06e-06	4.48e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CB—ovarian cancer	1.05e-06	4.45e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT1—ovarian cancer	1.05e-06	4.43e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	9.33e-07	3.94e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CA—ovarian cancer	9.24e-07	3.9e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTEN—ovarian cancer	9.11e-07	3.84e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	8.13e-07	3.43e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CA—ovarian cancer	8.05e-07	3.4e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CA—ovarian cancer	7.58e-07	3.2e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AKT1—ovarian cancer	7.55e-07	3.19e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTEN—ovarian cancer	7.03e-07	2.97e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AKT1—ovarian cancer	6.57e-07	2.78e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CA—ovarian cancer	6.42e-07	2.71e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKT1—ovarian cancer	6.19e-07	2.62e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKT1—ovarian cancer	5.25e-07	2.22e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	4.96e-07	2.09e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKT1—ovarian cancer	4.05e-07	1.71e-06	CbGpPWpGaD
